When PPARγ activity is disrupted, fatty acid oxidation is impaired, leading to excessive hepatic lipid accumulation, insulin resistance, and inflammation, key drivers of MASLD progression [5]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.